EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population

Hyoung Il Choi, Jae Myung Cha iD, Young Sang Kim, Dae Hyeon Cho, Han Ju Pack, Soo-Young Na, Ji Hye Kim, Hyun Gun Kim, Young-Jin Park, Hye Jung Kwon, Kyeong Ok Kim, Geon Ho Lee und 1 weitere

The Korean Journal of Gastroenterology · 2026

DOI: 10.4166/kjg.2025.129 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Korean Journal of Gastroenterology, 2026. Verfasst von Hyoung Il Choi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Syndecan-2, Feces, DNA Methylation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Programmatic screening for colorectal cancer (CRC) could maximize the impact of screening in the average-risk population, but the diagnostic performance of a stool DNA-based Syndecan-2 methylation (meSDC2) test has only been reported in case-control studies or high-risk populations. This study examined the performance of a stool DNA-based meSDC2 test for CRC in an average-risk population from a real-world setting.

Methods

This retrospective, multicenter study included consecutive asymptomatic, average-risk individuals for CRC who completed a meSDC2 stool test at 18 hospitals. The clinical performance of the meSDC2 stool test, including the positive rate, adherence to confirmatory colonoscopy, and the positive predictive value (PPV) for colorectal neoplasia (CRN), was assessed.

Results

Over 54 months, 4,910 individuals completed the meSDC2 stool test, with 249 (5.1%) testing positive. The colonoscopy compliance rate after a positive test was 61.0% (n=152). Among 121 individuals with available colonoscopy data, the PPV for any CRN, advanced neoplasia, and CRC were 39.7%, 12.4%, and 2.5%, respectively. Colonoscopy after a positive meSDC2 test ensured a high-quality examination, as reflected by the 100% cecal intubation rate, 97.5% adequate preparation quality, and an average withdrawal time of 11.2 min. Among those with a positive meSDC2 test, a family history of CRC was a significant predictor of any CRN (p=0.029) and advanced neoplasia (p=0.003).

Conclusions

A stool DNA-based meSDC2 test in average-risk individuals for CRC revealed a high PPV for any CRN in a real-world setting, highlighting its potential as a screening modality in programmatic CRC screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsSyndecan-2FecesDNA MethylationHumansMaleFemaleMiddle AgedRetrospective StudiesAgedColonoscopyEarly Detection of CancerROC CurvePredictive Value of TestsAdult

Stichwörter der Autor:innen

BiomarkersColorectal neoplasmsDNA methylationFecesMass screening

Substanzen

Syndecan-2SDC2 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
  • Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Korea.
  • Department of Family Medicine, CHA Bundang Medical Center, CHA University, Seoul, Korea.
  • Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University of Medicine, Changwon, Korea.
  • Department of Family Medicine, Yuseong Sun Hospital, Daejeon, Korea.
  • Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.

ORCID-Profile: Jae Myung Cha

Zitieren

APA

Choi, H. I., Cha, J. M., Kim, Y. S., Cho, D. H., Pack, H. J., Na, S. Y., Kim, J. H., Kim, H. G., Park, Y. J., Kwon, H. J., Kim, K. O., Lee, G. H., & Lee, Y. J. (2026). Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population. The Korean Journal of Gastroenterology. https://doi.org/10.4166/kjg.2025.129

Vancouver

Choi HI, Cha JM, Kim YS, Cho DH, Pack HJ, Na SY, et al. Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population. The Korean Journal of Gastroenterology. 2026. doi:10.4166/kjg.2025.129

BibTeX
@article{Choi2026,
  author = {Choi, Hyoung Il and Cha, Jae Myung and Kim, Young Sang and Cho, Dae Hyeon and Pack, Han Ju and Na, Soo-Young and Kim, Ji Hye and Kim, Hyun Gun and Park, Young-Jin and Kwon, Hye Jung and Kim, Kyeong Ok and Lee, Geon Ho and Lee, Yoo Jin},
  title = {Stool DNA-based SDC2 Methylation Test for the Screening of Colorectal Neoplasia in an Asymptomatic, Average-Risk Population},
  journal = {The Korean Journal of Gastroenterology},
  year = {2026},
  doi = {10.4166/kjg.2025.129}
}
Kostenlos starten →